LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
After receiving neoadjuvant treatment with PD-1 antibody and undergoing radical resection, a total 36 to 45 NSCLC patients who met the inclusion criteria, will be randomly assigned in a 1:1:1 ratio to the experimental group 1, experimental group 2 and the control group in this Phase IIa clinical trial. The study will be followed up until 24 to 36 months after treatment.
Epistemonikos ID: e85e49adaacaabab624b786dfafe902c7199b18a
First added on: Mar 04, 2026